Sunesis Pharmaceuticals, Inc. (SNSS) financial statements (2021 and earlier)

Company profile

Business Address 395 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:20291432434643
Cash and cash equivalents2013142782722
Short-term investments 16 5352021
Other undisclosed cash, cash equivalents, and short-term investments   00(0)0
Restricted cash and investments 6     
Other undisclosed current assets2221111
Total current assets:22361533434744
Noncurrent Assets
Operating lease, right-of-use asset01
Property, plant and equipment 000000
Other noncurrent assets100    
Other undisclosed noncurrent assets   1   
Total noncurrent assets:1101000
TOTAL ASSETS:23371534434744
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3335679
Accounts payable0112223
Accrued liabilities1112233
Employee-related liabilities1111222
Debt 677389
Derivative instruments and hedges, liabilities      4
Deferred revenue and credits 123
Other undisclosed current liabilities0111123
Total current liabilities:391113111928
Noncurrent Liabilities
Long-term debt and lease obligation 0  11  
Long-term debt, excluding current maturities    11  
Operating lease, liability 0
Liabilities, other than long-term debt 000013
Deferred revenue and credits  13
Other liabilities 0000  
Total noncurrent liabilities: 0001113
Total liabilities:3101113222030
Stockholders' equity
Stockholders' equity attributable to parent2028422212714
Preferred stock61221211916 
Common stock0000000
Additional paid in capital719699642633600570536
Accumulated other comprehensive income (loss) 0 (0)(0)(0)(0)
Accumulated deficit(704)(683)(659)(633)(597)(559)(523)
Total stockholders' equity:2028422212714
TOTAL LIABILITIES AND EQUITY:23371534434744

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:0201336
Operating expenses(22)(25)(26)(35)(39)(42)(51)
Operating loss:(22)(23)(26)(34)(36)(39)(45)
Nonoperating income
(Other Nonoperating income)
1000044
Interest and debt expense(0)(1)(1)(1)(2)(1)(2)
Loss from continuing operations before equity method investments, income taxes:(22)(23)(27)(35)(38)(37)(43)
Other undisclosed income from continuing operations before income taxes0      
Loss before gain (loss) on sale of properties:(22)(23)(27)(35)(38)(37)(43)
Other undisclosed net loss(0)      
Net loss available to common stockholders, basic:(22)(23)(27)(35)(38)(37)(43)
Other undisclosed net loss available to common stockholders, diluted      (4)
Net loss available to common stockholders, diluted:(22)(23)(27)(35)(38)(37)(47)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(22)(23)(27)(35)(38)(37)(43)
Comprehensive loss:(22)(23)(27)(35)(38)(37)(43)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000(0)(0)(0)
Comprehensive loss, net of tax, attributable to parent:(22)(23)(27)(35)(38)(37)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: